Espadilla, Crispina L.
HRN: 23-01-29 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/21/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/21/2025
02/28/2025
IV
500mg
Q8
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes